BioCentury | Nov 7, 2020
Regulation

Aducanumab panel criticizes FDA as it rebukes Alzheimer’s candidate

...market cap of $50.6 billion.The road aheadSeveral amyloid therapies remain in development for Alzheimer’s, including BAN2401...
BioCentury | Dec 6, 2019
Clinical News

Biogen Alzheimer’s data won’t sway believers or doubters either way

...that have shown an effect on cognition in early trials, such as Alzheon’s ALZ-801 or BAN2401...
...Ltd. (Tokyo:5483), the greatest benefit was seen in APOE4 patients (see “ Data Raise Possibility BAN2401...
...is an oral small molecule prodrug of tramiprosate, an inhibitor of amyloid formation and neurotoxicity; BAN2401...
BioCentury | Sep 14, 2019
Clinical News

One amyloid candidate left for Biogen, Eisai after axing BACE trials

...from the amyloid hypothesis of Alzheimer’s disease. The partners' Phase III trial of anti-amyloid mAb BAN2401...
...Biogen did not respond in time for comment. The companies partnered to develop elenbecestat and BAN2401...
...BAN2401 for early AD a day later (see “Aggregating Hypotheses” ; “Biogen’s Lead Balloon” ). BAN2401...
BioCentury | Jul 12, 2019
Clinical News

Amyloid hypothesis takes first hit in an Alzheimer’s prevention setting

...elenbecestat in early 2020: one as monotherapy, and the other in combination with anti-amyloid mAb BAN2401...
...Targets: APOE - Apolipoprotein E; BACE1 - Beta-site APP-cleaving enzyme 1 Elizabeth S. Eaton, Staff Writer ACI-24 BAN2401 CNP520 elenbecestat...
BioCentury | May 10, 2019
Financial News

New Eisai venture arm to focus on digital tech, dementia, cancer

...the Japanese company and the Alzheimer's Clinical Trials Consortium (ACTC) have selected anti-β amyloid therapy BAN2401...
...comprising BAN2401 and Eisai’s β-site APP-cleaving enzyme (BACE) inhibitor elenbecestat. Eisai, which has rights to BAN2401...
...under a 2007 deal, is also conducting the Phase III Clarity AD/Study 301 trial of BAN2401...
BioCentury | May 4, 2019
Product Development

How the amyloid hypothesis holds its grip

...that conclusion, Eisai announced on March 22 it would start a Phase III trial of BAN2401...
...symptomatic patients. He thinks the target should be abandoned in the setting “only if” Eisai’s BAN2401...
...Medical School and co-director of the Center for Neurologic Diseases at Brigham and Women’s Hospital. BAN2401’s...
BioCentury | May 4, 2019
Product Development

Amyloid: how did we get here and what can we learn?

Unlike any other theory in drug development, the amyloid hypothesis of Alzheimer’s disease has maintained an almost cult-like following, despite two decades littered with a long line of late-stage failures and not a single success....
BioCentury | Apr 24, 2019
Company News

Biogen reiterates late-stage M&A priority as it calls off planned aducanumab trial

...Biogen is analyzing data from ENGAGE, EMERGE and a Phase II study of β-amyloid inhibitor BAN2401...
...the development" of its remaining β-amyloid programs: elenbecestat, a beta-site APP-cleaving enzyme (BACE) inhibitor, and BAN2401...
...was down $5.81 to $224.40 Wednesday. Consensus figures provided by FactSet. Elizabeth S. Eaton, Staff Writer aducanumab (BIIB037) BAN2401 elenbecestat...
BioCentury | Mar 25, 2019
Financial News

Biogen announces $5B stock buyback on heels of Alzheimer’s hit

...of high-risk patients across the treatment and placebo arms for another anti-β amyloid Alzheimer's candidate, BAN2401...
BioCentury | Mar 23, 2019
Product Development

Baby steps beyond beta amyloid

...hypothesis, announcing March 22 that it would start the Phase III Clarity AD trial of BAN2401...
...trial, but Eisai is leading development of the compound under their 2014 deal to co-develop BAN2401...
...the stock’s March 2015 high. Eisai announced Friday it would start Phase III testing of BAN2401...
Items per page:
1 - 10 of 48